Eur J Endocrinol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


DOI: 10.1530/eje.0.1510251
European Journal of Endocrinology, Vol 151, Issue 2, 251-257
Copyright © 2004 by European Society of Endocrinology
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ciarmela, P
Right arrow Articles by Petraglia, F
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ciarmela, P
Right arrow Articles by Petraglia, F

Articles

Follistatin-related gene expression, but not follistatin expression, is decreased in human endometrial adenocarcinoma

P Ciarmela, P Florio, M Sigurdardottir, P Toti, V Maguer-Satta, R Rimokh, A Altomare, P Tosi, and F Petraglia

Department of Pediatrics, Obstetrics and Reproductive Medicine, University of Siena, Siena, Italy.

OBJECTIVE: Activin A is a multifunctional growth and cell differentiation factor produced by normal endometrium, and secreted in high amounts by endometrial adenocarcinoma. In the present study we evaluated the expression of two inhibitory activin A ligands, follistatin and follistatin-related gene (FLRG), in endometrial adenocarcinoma and in age-matched healthy human endometrium. DESIGN AND METHODS: Atropic menopausal (n=13) and tumoral (n=9 adenocarcinoma) tissues were processed to evaluate mRNA expression levels (by semiquantitative RT-PCR) and peptide localization (by immunohistochemistry). Differences were evaluated by the unpaired t-test and assumed to be statistically significant when P<0.05. RESULTS: Both control and tumoral endometrial samples express and localize follistatin and FLRG. However, whereas follistatin mRNA expression did not differ significantly, FLRG was significantly lower in endometrial adenocarcinoma than in healthy endometrial specimens (P<0.0001). With respect to the localization of proteins, follistatin was immunolocalized in endometrial epithelial and vascular cells both in tumoral and healthy endometrium without any significant difference in intensity. Nuclear and cytoplasmic FLRG immunolocalization was seen in glands, and only nuclear immunolocalization was found in stroma and vessels of healthy endometrium. FLRG was weakly immunostained in endometrial adenocarcinoma. CONCLUSIONS: Whilst follistatin expression is unchanged, FLRG is down-regulated in endometrial carcinoma. As activin A is a differentiation factor of human endometrium, the present findings support an imbalance between increased activin A and decreased FLRG expression in endometrial cancer, so that the failure of the activin A pathway through FLRG may be pivotal in endometrial tumorigenesis.


This article has been cited by other articles:


Home page
EndocrinologyHome page
P. Ciarmela, E. Wiater, and W. Vale
Activin-A in Myometrium: Characterization of the Actions on Myometrial Cells
Endocrinology, May 1, 2008; 149(5): 2506 - 2516.
[Abstract] [Full Text] [PDF]


Home page
Hum Reprod UpdateHome page
C. Ferretti, L. Bruni, V. Dangles-Marie, A.P. Pecking, and D. Bellet
Molecular circuits shared by placental and cancer cells, and their implications in the proliferative, invasive and migratory capacities of trophoblasts
Hum. Reprod. Update, March 1, 2007; 13(2): 121 - 141.
[Abstract] [Full Text] [PDF]


Home page
Eur J EndocrinolHome page
P. Florio, P. Ciarmela, F. M Reis, P. Toti, L. Galleri, R. Santopietro, E Tiso, P. Tosi, and F. Petraglia
Inhibin {alpha}-subunit and the inhibin coreceptor betaglycan are downregulated in endometrial carcinoma
Eur. J. Endocrinol., February 1, 2005; 152(2): 277 - 284.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 European Society of Endocrinology.